ストックスクリーナーアプリを入手
1.92
72.61%
-5.09
前日終値:
$7.01
開ける：
$2.19
24時間の取引高:
21.96M
Relative Volume:
44.41
時価総額：
$43.51M
収益：
$151.12M
当期純損益:
$-194.97M
株価収益率:
-0.1273
EPS:
-15.0871
ネットキャッシュフロー:
$-59.11M
1週間 パフォーマンス:
-74.09%
1か月 パフォーマンス:
-80.35%
6か月 パフォーマンス:
-70.55%
1年 パフォーマンス:
-49.61%
1日の値動き範囲:
$1.80
$2.43
1週間の範囲:
$1.80
$7.84
52週間の値動き範囲:
$1.80
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
名前
Karyopharm Therapeutics Inc
セクター
電話
617-658-0600
住所
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
1.92 | 160.68M | 151.12M | -194.97M | -59.11M | -15.09 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Rodman & Renshaw | Buy |
| 2026-02-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-13 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 再開されました | H.C. Wainwright | Buy |
| 2023-01-19 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-08-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 開始されました | Morgan Stanley | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-07-23 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-05 | 繰り返されました | Robert W. Baird | Outperform |
| 2019-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 開始されました | B. Riley FBR | Buy |
| 2018-11-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-05-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-04-02 | 再開されました | Leerink Partners | Outperform |
| 2017-11-15 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2016-09-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | アップグレード | Jefferies | Hold → Buy |
| 2016-08-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-28 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates - Kalkine
Karyopharm Therapeutics Inc (KPTI) Cash Flow - TradingKey
Karyopharm Therapeutics Inc (KPTI) Balance Sheet - TradingKey
KPTI|Karyopharm Therapeutics Inc|Price:7.410|Chg%:+0.320 - TradingKey
Karyopharm Therapeutics Inc (KPTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KPTI|Karyopharm Therapeutics Inc|Price:7.605|Chg%:+0.195 - TradingKey
Karyopharm Therapeutics Inc (KPTI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Karyopharm Therapeutics Inc (KPTI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Karyopharm stock trades lower after revenue declines and cash burn widens - Ad-hoc-news.de
KPTI Q2'26 Earnings: revenue estimate is 33.12M USD - TradingView
Karyopharm Therapeutics Inc (KPTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Karyopharm: 'Hold' Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI) - Seeking Alpha
RBC Capital reiterates Karyopharm stock rating on compensation plan By Investing.com - Investing.com Canada
Karyopharm drops 21% following disclosure of executive cash retention plan - MSN
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI) - Seeking Alpha
Karyopharm Pharmaceuticals (KPTI) Sees 21% Drop Amid Leadership Cash Retention Program - GuruFocus
KPTI Shares Drop Significantly After Compensation Plan Update - GuruFocus
Karyopharm Therapeutics (KPTI) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Stocks to Wtach: Karyopharm Therapeutics, MKDWELL, Advanced Biomed - Moomoo
Karyopharm Therapeutics Slides on Disclosure of Cash-Retention Program for Executives - Moomoo
Karyopharm Therapeutics Launches 2026 Leadership Cash Retention Program for Key Executives - Minichart
Karyopharm Launches 2026 Executive Retention Incentive Program - TipRanks
Karyopharm Therapeutics (NASDAQ: KPTI) grants 2026 cash retention awards to key executives - Stock Titan
KPTI5813817 Bond Coupon Profile — Rate & Payments - TradingView
KPTI5813817 Bond Risk Profile - TradingView
KPTI5813817 Bond Profile — Key Metrics - TradingView
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm stock trades steadily as investors watch Selinexor franchise - AD HOC NEWS
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Karyopharm Therapeutics faces a data setback as investors weigh late-stage cancer pipeline - Ad Hoc News
KPTIKaryopharm Therapeutics Inc Latest SEC Filings - Finviz
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm gives 4 new hires stock awards vesting over 3 years - Stock Titan
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Value Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2500 Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000E Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2500 Index - marketscreener.com
Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Price to sales forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000 Index - marketscreener.com
Price to earnings forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Enterprise value to revenue forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $KPTI - MarketBeat
Karyopharm Therapeutics Inc (KPTI) 財務データ
収益
当期純利益
現金流量
EPS
Karyopharm Therapeutics Inc (KPTI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rangwala Reshma | EVP & Chief Medical Officer |
May 14 '26 |
Sale |
9.50 |
408 |
3,876 |
56,829 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
May 14 '26 |
Sale |
9.50 |
324 |
3,078 |
107,940 |
| Abate Kristin | Chief Accounting Officer |
May 14 '26 |
Sale |
9.50 |
53 |
504 |
23,801 |
| Paulson Richard A. | President and CEO |
May 14 '26 |
Sale |
9.50 |
2,203 |
20,928 |
269,747 |
| Mano Michael | EVP, CLO&Secretary |
May 14 '26 |
Sale |
9.50 |
266 |
2,527 |
94,398 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 21 '26 |
Sale |
8.94 |
449 |
4,014 |
56,290 |
| Mano Michael | EVP, CLO&Secretary |
Mar 02 '26 |
Sale |
9.41 |
3,526 |
33,178 |
93,964 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 02 '26 |
Sale |
9.41 |
5,066 |
47,669 |
56,739 |
| Paulson Richard A. | President and CEO |
Mar 02 '26 |
Sale |
9.41 |
12,361 |
116,311 |
267,030 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 17 '26 |
Sale |
8.63 |
378 |
3,262 |
99,429 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):